Update on arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 4, 2013, Pages 476-487

  James, Cynthia A ^a   Calkins, Hugh ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Arrhythmogenic cardiomyopathy; Arrhythmogenic right ventricular cardiomyopathy; Arrhythmogenic right ventricular dysplasia; Arrhythmogenic right ventricular dysplasia cardiomyopathy; Cardiac desmosome; Implantable cardioverter defibrillator; Ventricular tachycardia, Epicardial ablation

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NITRATE; SOTALOL;

ARTICLE; CARDIAC IMAGING; CATHETER ABLATION; CLINICAL EVALUATION; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; EXERCISE; GENETIC SCREENING; HEART ARRHYTHMIA; HEART GRAFT; HEART PROTECTION; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL DECISION MAKING; NONHUMAN; PATIENT COUNSELING; PREGNANT WOMAN; RADIOFREQUENCY ABLATION; SCREENING TEST; SUDDEN CARDIAC DEATH;

EID: 84881040974     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0251-8     Document Type: Article

References (52)

1. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289-300.
2. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129-33.
3. Marcus F, Fontaine G, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384-98.
4. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia. Circulation. 2005;112:3823-32.
5. Dalal D, James C, Devanagondi R, et al. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006;48:1416-24.
6. Murray B. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C): a review of molecular and clinical literature. J Genet Couns. 2012;21:494-504.
7. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710-20.
8. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701-9.
9. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation. 2003;108:3000-5.
10. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994;71:215-8.
11. •• Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806-14. This is a publication of revised diagnostic criteria for ARVD/C that are now widely accepted and should be used for clinical diagnosis. These criteria were designed to improve sensitivity and specificity of diagnostic criteria. Changes included use of quantitative parameters for evaluation of the right ventricle by cardiac MR and echocardiography, incorporation of genetic testing into the criteria, and changes in scoring of subtle repolarization and depolarization abnormalities.
12. Protonotarios N, Anastasakis A, Antoniades L, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations. Eur Heart J. 2011;32:1097-104.
13. Cox MG, van der Smagt JJ, Wilde AA, et al. New ECG criteria in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2009;2:524-30.
14. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355:2119-24.
15. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002;71:1200-6.
16. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36:1162-4.
17. Awad MM, Dalal D, Cho E, et al. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet. 2006;79:136-42.
18. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006;79:978-84.
19. Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. 2008;82:809-21.
20. Taylor M, Graw S, Sinagra G, et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation. 2011;124:876-85.
21. van der Zwaag PA, van Rijsingen IA, Asimaki A, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199-207.
22. Klauke B, Kossmann S, Gaertner A, et al. De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy. Hum Mol Genet. 2010;19:4595-607.
23. den Haan AD, Tan BY, Zikusoka MN, et al. Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009;2:428-35.
24. •• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace. 2011;13:1077-109. This joint position statement of the Heart Rhythm Society of North America and the European Heart Rhythm Association provides specific recommendations for the utilization of genetic testing for ARVD/C as well as for other inherited cardiomyopathies and arrhythmia syndromes.
25. Saffitz JE. Arrhythmogenic cardiomyopathy: advances in diagnosis and disease pathogenesis. Circulation. 2011;124:e390-2.
26. Delmar M, McKenna WJ. The cardiac desmosome and arrhythmogenic cardiomyopathies from gene to disease. Circ Res. 2010;107:700-14.
27. Hoffmayer KS, Machado ON, Marcus GM, et al. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Coll Cardiol. 2011;58:831-8.
28. Asimaki A, Tandri H, Duffy ER, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhy Electrophysiol. 2011;4:743-52.
29. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. New Engl J Med. 2009;360:1075-84.
30. Dechering DG, Kochhäuser S, Wasmer K, et al. Electrophysiologic characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2013;10:158-64.
31. Steckman DA, Schneider PM, Schuller JL, et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2012;110:575-9.
32. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011;57:2317-27.
33. Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/ defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2004;109:1503-8.
34. Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2005;2:1188-94.
35. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144-52. This paper describes outcomes among106 ARVD/C patients who received an ICD for primary prevention. During a mean follow up of 58 ± 35 months, 24 % had an appropriate ICD discharge, and 16 % a shock for ventricular fibrillation/flutter. A history of syncope was associated with appropriate ICD interventions. None of 27 asymptomatic patients with isolated familial sudden death required appropriate ICD therapy. Twenty patients had inappropriate ICD interventions and 18 had device-related complications.
36. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58:1485-96. This study described 84 North American ARVD/C patients who underwent ICD implantation for primary prevention over a mean follow up of 4.7 ± 3.4 years. Appropriate ICD therapy was seen in 40 (48 %) patients, of which 16 (19 %) received interventions for rapid ventricular arrhythmias. Inducibility at EP study and history of nonsustained ventricular tachycardia were significant predictors of appropriate ICD discharge in multivariable analysis. These findings are important, as they demonstrate that nearly half of the ARVD/C patients treated with an ICD for primary prevention experienced appropriate ICD interventions.
37. James CA, Tichnell C, Murray B, et al. General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. Circ Cardiovasc Genet. 2012;5:18-24. This study reports psychological outcomes for 87 adult ARVD/C patients with ICDs. One-third had clinically significant anxiety and one-tenth had clinically significant depression. Young ARVD/C patients had significant body image concerns and distress related to their device. Both generalized and device-specific anxiety were elevated beyond what is the norm for ICD patients. Poor device adjustment, while unfavorable in and of itself, was additionally associated with increased likelihood of clinically significant depression and anxiety. Factors associated with poor adjustment included: 1) younger age, 2) having a device implanted recently, 3) having at least one ICD shock, and 4) having a poorer functional capacity.
38. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29-37.
39. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: A report from the North American ARVC registry. J Am Coll Cardiol. 2009;54:609-15.
40. Fabritz L, Hoogendijk MG, Scicluna BP, et al. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol. 2011;57:740-50. This study used a murine model of ARVD/C carrying a heterozygous plakoglobin deletion to test the utility of load-reducing therapy (furosemide and nitrates) at preventing training-induced right ventricular enlargement and arrhythmias. Load reducing therapy appeared effective at changing cardiac response to exercise as therapy prevented training-induced right ventricular enlargement and ventricular tachycardias were less often induced in isolated hearts of treated plakoglobin+ hearts than in hearts of untreated plakoglobin+ littermates.
41. Calkins H. Use of mouse models to evaluate novel therapeutic approaches to treatment of arrhythmogenic right ventricular cardiomyopathy: the future is now. J Am Coll Cardiol. 2011;57:751-2.
42. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009;120:366-75.
43. Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhy Electrophysiol. 2011;4:478-85. This paper assessed survival from recurrent ventricular tachycardia among 49 ARVD/C patients in the US, Italy, Colombia, and Canada undergoing catheter ablation using an epicardial-alone approach (23 patients) or an endo-epicardial ablation (26 patients). After a minimum 3-year follow-up, freedom from recurrent ventricular arrhythmia was significantly greater among those who had undergone combined endo-epicardial ablation (52 % vs. 85 %).
44. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circ Arrhy Electrophysiol. 2012;5:499-505. This study reported on 87 ARVD/C patients who underwent a total of 175 catheter ablation procedures. Over a mean follow-up of 88 ± 66 months, the overall freedom of ventricular tachycardia was 47 %, 21 %, and 15 % at 1, 5, and 10 years, respectively. The cumulative freedom from ventricular tachycardia following epicardial ablation was 64 % and 45 % at 1 and 5 years. Importantly, the burden of ventricular tachycardia decreased following ablation from a median of 0.16 VT episodes per month pre ablation to 0.08 episodes per month post ablation, with the best results occurring among patients treated by epicardial ablation.
45. Tedford RJ, James C, Judge DP, et al. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2012;59:289-90. This paper describes 18 ARVD/C patients who required cardiac transplant. The average age of first ARVD/C symptoms was 24 ± 13 years (median age 18 years). The two most common clinical reasons for initial presentation were heart failure in five patients (28 %) and sustained VT in five patients (28 %). The average age at cardiac transplant was 40 ± 14 years (median age 44 years). Thirteen patients received transplants primarily as a result of heart failure symptoms (biventricular failure in four patients, predominately right ventricular failure in four patients, right ventricular failure only in five patients), and five received transplants for predominately ventricular tachycardia. Most patients who received transplants for heart failure had a prolonged clinical course of ARVD/C and heart failure symptom onset (17.6 ± 13.3 years and 7.2 ± 6.4 years, respectively).
46. Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005;45:1340-5.
47. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004;109:2807-16.
48. Corrado D, Basso C, Rizzoli G, et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42:1959-63.
49. Kirchhof P, Fabritz L, Zwiener M, et al. Age-and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114:1799-806.
50. Saffitz JE, Asimaki A, Huang H. Arrhythmogenic right ventricular cardiomyopathy: new insights into mechanisms of disease. Cardiovasc Pathol. 2010;19:166-70.
51. James CA, Bhonsale A, Tichnell C, et al. Exercise increases penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Heart Rhythm. 2013;10:S90.
52. Bauce B, Daliento L, Frigo G, et al. Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod Biol. 2006;127:186-9.